Clinical Trial Update: Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial is evaluating the combination of durvalumab (anti-PD-L1) with rintatolimod (TLR-3 agonist) in metastatic pancreatic ductal adenocarcinoma, c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Rintatolimod (rintatolimod)

Snippet

Sponsor: Joachim Aerts, MD PhD | Conditions: Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING